Literature DB >> 24133592

Clinical significance of NOB1 expression in breast infiltrating ductal carcinoma.

Xiao-Yu Li1, Qi-Feng Luo, Jia Li, Chuan-Kui Wei, Xiang-Jie Kong, Jun-Feng Zhang, Lin Fang.   

Abstract

BACKGROUND: NIN/RPN Binding protein 1 homologue (NOBp1), encoded by NOB1 gene, was reported to play an essential role in the oncogenesis and prognosis of carcinomas. We conducted a study to reveal its expression and clinical significance in breast infiltrating ductal carcinoma.
METHODS: To explore the relationship between NOB1 expression and the clinical TNM (cTNM), 162 patients who undergone surgery were involved in the study. Compared to healthy tissues, abnormal localization and higher level of NOB1 in tumor cells was observed by Immunohistochemistry staining. Real-time PCR and western-blotting verified the up-regulation of NOB1 in carcinoma individuals.
RESULTS: A significant correlation between high level of NOB1 and the T stage, lymph node metastasis and cTNM was shown. Furthermore, patients with higher level of NOB1 predicted a declined overall survival (OS). Notably, multivariate analyses by Cox's proportional hazard model revealed that expression of NOB1 was an independent prognostic factor in breast infiltrating ductal carcinoma.
CONCLUSIONS: In summary, our present study clarify that the aberrant expression of NOB1 in breast infiltrating ductal carcinoma is possibly involved with tumorigenesis and development, and the NOB1 protein could act as a potential biomarker for prognosis assessment of breast infiltrating ductal carcinoma. Related mechanism is worthy of further investigation.

Entities:  

Keywords:  Breast cancer; NOB1 protein; immunohistochemistry; tissue microarray

Mesh:

Substances:

Year:  2013        PMID: 24133592      PMCID: PMC3796236     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  25 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

Review 2.  The 26S proteasome: a molecular machine designed for controlled proteolysis.

Authors:  D Voges; P Zwickl; W Baumeister
Journal:  Annu Rev Biochem       Date:  1999       Impact factor: 23.643

Review 3.  Protein degradation by the ubiquitin-proteasome pathway in normal and disease states.

Authors:  Stewart H Lecker; Alfred L Goldberg; William E Mitch
Journal:  J Am Soc Nephrol       Date:  2006-05-31       Impact factor: 10.121

4.  Nob1 binds the single-stranded cleavage site D at the 3'-end of 18S rRNA with its PIN domain.

Authors:  Allison C Lamanna; Katrin Karbstein
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-14       Impact factor: 11.205

5.  Backbone and side chain NMR resonance assignments for an archaeal homolog of the endonuclease Nob1 involved in ribosome biogenesis.

Authors:  Thomas Veith; Jan Philip Wurm; Elke Duchardt-Ferner; Benjamin Weis; Roman Martin; Charlotta Safferthal; Markus T Bohnsack; Enrico Schleiff; Jens Wöhnert
Journal:  Biomol NMR Assign       Date:  2011-07-06       Impact factor: 0.746

6.  [Expression of NOB1 and its significance in colorectal cancer].

Authors:  Dong-Ping Wu; Xiao-Wen He
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2012-03

7.  The putative NTPase Fap7 mediates cytoplasmic 20S pre-rRNA processing through a direct interaction with Rps14.

Authors:  Sander Granneman; Madhusudan R Nandineni; Susan J Baserga
Journal:  Mol Cell Biol       Date:  2005-12       Impact factor: 4.272

8.  z-Leucinyl-leucinyl-norleucinal induces apoptosis of human glioblastoma tumor-initiating cells by proteasome inhibition and mitotic arrest response.

Authors:  Massimiliano Monticone; Emanuela Biollo; Andrea Fabiano; Marina Fabbi; Antonio Daga; Francesco Romeo; Massimo Maffei; Alice Melotti; Walter Giaretti; Giorgio Corte; Patrizio Castagnola
Journal:  Mol Cancer Res       Date:  2009-10-27       Impact factor: 5.852

9.  Nob1p is required for biogenesis of the 26S proteasome and degraded upon its maturation in Saccharomyces cerevisiae.

Authors:  Yoshiko Tone; Akio Toh-E
Journal:  Genes Dev       Date:  2002-12-15       Impact factor: 11.361

10.  Early contralateral shoulder-arm morbidity in breast cancer patients enrolled in a randomized trial of post-surgery radiation therapy.

Authors:  Nele Adriaenssens; Vincent Vinh-Hung; Geertje Miedema; Harijati Versmessen; Jan Lamote; Marian Vanhoeij; Pierre Lievens; Hilde van Parijs; Guy Storme; Mia Voordeckers; Mark De Ridder
Journal:  Breast Cancer (Auckl)       Date:  2012-07-30
View more
  8 in total

1.  MicroRNA-215 targets NOB1 and inhibits growth and invasion of epithelial ovarian cancer.

Authors:  Yang Lin; Yang Jin; Tianmin Xu; Shunqing Zhou; Manhua Cui
Journal:  Am J Transl Res       Date:  2017-02-15       Impact factor: 4.060

2.  Evaluation of NIN/RPN12 binding protein inhibits proliferation and growth in human renal cancer cells.

Authors:  Jian-wei Jia; Ai-qin Liu; Yun Wang; Fen Zhao; Li-ling Jiao; Jun Tan
Journal:  Tumour Biol       Date:  2014-11-26

3.  Anticancer activity of NOB1-targeted shRNA combination with TRAIL in epithelial ovarian cancer cells.

Authors:  Yang Lin; Tianmin Xu; Hong Teng; Manhua Cui
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

4.  Nin one binding protein expression as a prognostic marker in prostate carcinoma.

Authors:  G Liu; D Shen; L Jiao; Y Sun
Journal:  Clin Transl Oncol       Date:  2014-02-04       Impact factor: 3.405

5.  Effects of NOB1 on the pathogenesis of osteosarcoma and its expression on the chemosensitivity to cisplatin.

Authors:  Leiming Luo; Yuanhui Wang; Yiran Yin; Jianhua Ge; Xiaobo Lu
Journal:  Oncol Lett       Date:  2018-01-04       Impact factor: 2.967

6.  LAMP1 expression is associated with poor prognosis in breast cancer.

Authors:  Qingqing Wang; Juan Yao; Qin Jin; Xudong Wang; Huijun Zhu; Fan Huang; Wei Wang; Jianfeng Qiang; Qichao Ni
Journal:  Oncol Lett       Date:  2017-08-16       Impact factor: 2.967

7.  MicroRNA-363-3p downregulation in papillary thyroid cancer inhibits tumor progression by targeting NOB1.

Authors:  Su Dong; Shuai Xue; Yue Sun; Zhe Han; Lele Sun; Jialu Xu; Jia Liu
Journal:  J Investig Med       Date:  2020-10-19       Impact factor: 2.895

8.  High Eg5 expression predicts poor prognosis in breast cancer.

Authors:  Qin Jin; Fang Huang; Xudong Wang; Huijun Zhu; Yun Xian; Jieying Li; Shu Zhang; Qichao Ni
Journal:  Oncotarget       Date:  2017-07-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.